Recent Communications
March 28, 2012
(Invitation to Informational Webinar –
Patient Advocacy Groups)
Patient Advocacy Groups)
December 22, 2011
(Invitation to Informational Webinar – Pharmaceutical Industry)
October 17, 2011
(Invitation to Informational Webinar – Pharmaceutical Industry)
Drug Review Updates
The pan-Canadian Oncology Drug Review (pCODR) began accepting submissions on July 13, 2011.
The following submissions have been made to pCODR:
- Sunitinib (Sutent) for pancreatic neuroendocrine tumours
(Notification to Implement Issued
Posted as of May 17, 2012)
- Ipilimumab (Yervoy) for advanced melanoma
(Notification to Implement Issued
Posted as of May 2, 2012)
- Pazopanib hydrochloride (Votrient) for soft tissue sarcoma
(Pending Submission as of April 20, 2012)
For other submissions currently under review or that we anticipate being made to pCODR, please visit Find a Review.
We encourage you to visit Submit & Contribute to register for submissions.
For information on the pCODR review process, please visit Our Review Process.
Submit & Contribute
Visit Submit & Contribute to register or to learn more information about:
- About the Submission Process
- Submit a Drug for Review
- Provide Feedback
This website is powered by Cancer View Canada